-5%
Renatrel, particularly its active stereoisomer levonorgestrel, operates by binding to progesterone and estrogen receptors located in various parts of the female reproductive system, including the reproductive tract, mammary gland, hypothalamus, and pituitary gland. Upon binding to these receptors, progestins like levonorgestrel decrease the frequency of gonadotropin-releasing hormone (GnRH) release from the hypothalamus and dampen the pre-ovulatory surge of luteinizing hormone (LH). The suppression of the LH surge effectively inhibits ovulation, thereby preventing pregnancy.
Renatrel (and more specifically the active stereoisomer levonorgestrel) binds to the progesterone and estrogen receptors within the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin-releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Loss of the LH surge inhibits ovulation and thereby prevents pregnancy.